Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01531686
Other study ID # 2011-02
Secondary ID
Status Terminated
Phase N/A
First received February 3, 2012
Last updated December 5, 2016
Start date March 2012
Est. completion date January 2014

Study information

Verified date December 2016
Source Vidacare Corporation
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Intraosseous vascular access can be used to effectively and safely deliver contrast dye for CT examination.


Description:

intraosseous vascular access in the proximal humerus can be used to delivery contrast dye for CT examination.


Recruitment information / eligibility

Status Terminated
Enrollment 8
Est. completion date January 2014
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Aged 18 years or older

- Has received intraosseous vascular access at the proximal humerus insertion site via EZ-IO as standard of care

- Requires CT examination with contrast media delivery via proximal humerus intraosseous catheter, as standard of care

- Cognitively and physically able to give written consent to participate in the study

Exclusion Criteria:

- Fracture in target bone, or significant trauma to the site

- Excessive tissue and/or absence of adequate anatomical landmarks in target bone

- Infection in target area

- IO insertion in past 24 hours, prosthetic limb or joint or other significant orthopedic procedure in target bone

- Allergy to contrast media

- Imprisoned

- Pregnant

- Requires English language translation other than Spanish

- Has received IO access with an IO catheter other than the EZ-IO system

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms

  • Intraosseous Vascular Access Patients Requiring CT Exam

Intervention

Procedure:
Intraosseous delivery of CT contrast dye
Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.

Locations

Country Name City State
United States Shands Critical Care Center and Cancer Hospital Gainesville Florida
United States Grand Strand Regional Medical Myrtle Beach South Carolina
United States Maricopa Medical Center Phoenix Arizona
United States Olive View UCLA Medical Center Sylmar California

Sponsors (1)

Lead Sponsor Collaborator
Vidacare Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adequate CT image ability to effectively administer the contrast medium needed for the indicated CT examination. at time of CT examination average time is within 24 hours No
Primary number of participants with adverse events within 24 hours of CT exam incidence of complications assocated with the administration of contrast medium through the intraosseous route. within 24 hours of CT exam Yes
Primary number of participants with adverse events within 30 days of CT exam within 30 days of CT exam Yes